Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mark A. Killick"'
Publikováno v:
Vaccine: X, Vol 12, Iss , Pp 100222- (2022)
Background: An ongoing challenge in HIV-1 vaccine research is finding a novel HIV-1 envelope glycoprotein (Env)-based immunogen that elicits broadly cross-neutralizing antibodies (bnAbs) without requiring complex sequential immunization regimens to d
Externí odkaz:
https://doaj.org/article/793d6ab891b14089ba9441c607000391
Publikováno v:
Virology Journal, Vol 19, Iss 1, Pp 1-15 (2022)
Abstract The recently published AMP trial (HVTN 703/HPTN 081 and HVTN704/HPTN 085) results have validated broad neutralising antibodies (bNAbs) as potential anti-HIV-1 agents. However, single bNAb preparations are unlikely to cope with the onslaught
Externí odkaz:
https://doaj.org/article/411fa744bd4346af8b3ce3776a0f721f
Publikováno v:
Retrovirology, Vol 16, Iss 1, Pp 1-12 (2019)
Abstract The existing repertoire of HIV-1 patient derived broadly neutralising antibodies (bNAbs) that target the HIV-1 envelope glycoprotein (Env) present numerous and exciting opportunities for immune-based therapeutic and preventative strategies a
Externí odkaz:
https://doaj.org/article/b98507aa6b744044ac4e266a91503950
Autor:
Nancy L. Tumba, Previn Naicker, Stoyan Stoychev, Mark A. Killick, Gavin R. Owen, Maria A. Papathanasopoulos
Publikováno v:
Biochemical and Biophysical Research Communications. 612:181-187
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) mediates host cell infection by binding to the cellular receptor CD4. Recombinant Env bound to CD4 has been explored for its potential as an HIV vaccine immunogen as receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e81e976171f066ef1a3e799cb1bd2ab5
https://doi.org/10.1016/j.bbrc.2022.04.101
https://doi.org/10.1016/j.bbrc.2022.04.101